| 产品名称 | AHU377钙盐CAS: 1369773-39-6原料供应发货南京工厂 |
|---|---|
| 公司名称 | 南京辰瑞晟生物医药科技有限公司 |
| 价格 | .00/件 |
| 规格参数 | 品牌:CRS 型号:CMO 产地:国产 |
| 公司地址 | 南京市雨花台区安德门大街57号楚翘城5幢503-008室（注册地址） |
| 联系电话 | 0571-87428035 15360676961 |
| 中文名 | AHU-377 hemicalcium salt |
| 英文名 | AHU-377 hemicalcium salt |
| 别名 | 沙库必曲钙盐 HU377钙盐 AHU377钙盐 原研534-06 LCZ696中间体 LCZ696中间体(AHU-377钙盐) AHU-377 钙盐1369773-39-6 (2R,4S)-5-(联苯-4-基)-4-(氨基)-5-(3-羧基-丙酰基氨基)-2甲基-戊酸乙酯钙盐 |
| 英文别名 | (alphar AHU-377 hemicalcium salt AHU-377 (heMicalciuM salt) LCZ696(valsartan + sacubitril) impurity 1 Ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl-[1,1'-biphenyl]-4-pentanoate hemicalcium salt Calciumbis(4-{[(1S,3R)-1-([1,1'-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl] amino} -4-oxobutanoate) |
| CAS | 1369773-39-6 |
| 化学式 | C48H56CaN2O10 |
| 分子量 | 861.04364 |
| 熔点 | >140°C (dec.) |
| 溶解度 | DMSO (Slightly, Heated), Methanol (Slightly) |
| 存储条件 | -20°C |
| 外观 | powder |
| 颜色 | white to beige |
| 体外研究 | Sacubitril (AHU-377) is a single molecule that is comprised of molecular moieties of valsartan, an ARB, and Sacubitril hemicalcium salt, a neprilysin inhibitor (1:1 ratio). Sacubitril (AHU-377) is converted by enzymatic cleavage of the ethyl ester into the active neprilysin inhibiting metabolite LBQ657. The inactive NEPi precursor, Sacubitril hemicalcium salt, does not inhibit collagen accumulation in fibroblasts nor cardiac myocyte hypertrophy. In cardiac fibroblasts, the active NEPi LBQ657 had no discernible effects. In contrast, LBQ657 modestly inhibits cardiac myocyte hypertrophy. |
| 体内研究 | In humans, Sacubitril (AHU-377)(t max 0.5-1.1 h) are absorbed quickly. Sacubitril hemicalcium salt is converted rapidly into LBQ657 with its t max being reached in 1.9-3.5 h. Mean t 1/2 values for the biologically active LBQ657 is 9.9-11.1 h.In vehicle-treated dogs, ANF increases urinary sodium excretion from 17.3±3.6 to 199.5±18.4 pequivkglmin. This effect is potentiated significantly in animals which receive Sacubitril (AHU-377). Urinary volume is also potentiated in animals which receive an iv administration of Sacubitril (AHU-377). |